MXPA04001878A - Medicinal compositions containing angiotensin ii receptor antagonist. - Google Patents
Medicinal compositions containing angiotensin ii receptor antagonist.Info
- Publication number
- MXPA04001878A MXPA04001878A MXPA04001878A MXPA04001878A MXPA04001878A MX PA04001878 A MXPA04001878 A MX PA04001878A MX PA04001878 A MXPA04001878 A MX PA04001878A MX PA04001878 A MXPA04001878 A MX PA04001878A MX PA04001878 A MXPA04001878 A MX PA04001878A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonist
- medicinal compositions
- compositions containing
- containing angiotensin
- angiotensin
- Prior art date
Links
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Medicinal compositions for administering an angiotensin II receptor antagonist and an ACAT inhibitor either at the same time or separately at a certain interval.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001257435 | 2001-08-28 | ||
PCT/JP2002/008629 WO2003020315A1 (en) | 2001-08-28 | 2002-08-27 | Medicinal compositions containing angiotensin ii receptor antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04001878A true MXPA04001878A (en) | 2004-06-15 |
Family
ID=19085097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04001878A MXPA04001878A (en) | 2001-08-28 | 2002-08-27 | Medicinal compositions containing angiotensin ii receptor antagonist. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040198788A1 (en) |
EP (1) | EP1421953A4 (en) |
KR (1) | KR20040032969A (en) |
CN (1) | CN1589154A (en) |
AU (1) | AU2002328569B9 (en) |
BR (1) | BR0212254A (en) |
CA (1) | CA2459017A1 (en) |
CO (1) | CO5560583A2 (en) |
HU (1) | HUP0401696A2 (en) |
IL (1) | IL160438A0 (en) |
MX (1) | MXPA04001878A (en) |
NO (1) | NO20041291L (en) |
NZ (1) | NZ531346A (en) |
PL (1) | PL368843A1 (en) |
RU (1) | RU2004105965A (en) |
WO (1) | WO2003020315A1 (en) |
ZA (1) | ZA200401603B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1604664A4 (en) * | 2003-01-31 | 2006-12-27 | Sankyo Co | MEDICINE FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND HYPERTENSION |
US20090226420A1 (en) * | 2005-11-10 | 2009-09-10 | Elizabeth Hauser | Methods of Determining the Risk of Developing Coronary Artery Disease |
KR101345876B1 (en) * | 2012-01-31 | 2013-12-30 | 인제대학교 산학협력단 | Composition for preserving cells, tissue or organs containing Fimasartan |
CN112979617A (en) * | 2019-12-17 | 2021-06-18 | 中国科学院苏州纳米技术与纳米仿生研究所 | Irbesartan piperazine salt and preparation method and application thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4771072A (en) * | 1985-01-10 | 1988-09-13 | Tanabe Seiyaku Co., Ltd. | Alkoxynaphthalene derivatives |
US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
EP0421441B1 (en) * | 1989-10-06 | 1995-01-25 | Fujirebio Inc. | Pantothenic acid derivatives |
DE122007000050I1 (en) * | 1990-02-19 | 2007-11-08 | Novartis Ag | acyl compounds |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
GB9025509D0 (en) * | 1990-11-23 | 1991-01-09 | Fujisawa Pharmaceutical Co | New amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
JP2650096B2 (en) * | 1990-11-26 | 1997-09-03 | 大正製薬株式会社 | Anilide derivative |
US5591762A (en) * | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
CA2229000C (en) * | 1991-02-21 | 2002-04-09 | Sankyo Company, Limited | 1-biphenylimidazole derivatives, their preparation and their therapeutic use |
US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
JP3720395B2 (en) * | 1994-09-20 | 2005-11-24 | 京都薬品工業株式会社 | Novel heterocyclic derivative, production method thereof and pharmaceutical use thereof |
DK0866059T3 (en) * | 1995-10-05 | 2002-03-25 | Kyoto Pharma Ind | New heterocyclic derivatives and their medical use |
FR2741619B1 (en) * | 1995-11-28 | 1998-02-13 | Pf Medicament | NOVEL 2,3,5-TRIMETHYL-4-HYDROXY-ANILIDES DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
CA2197364A1 (en) * | 1996-02-15 | 1997-08-16 | Toshikazu Suzuki | Phenol compound and process for preparing the same |
JPH11228416A (en) * | 1997-10-23 | 1999-08-24 | Takeda Chem Ind Ltd | Lipid reducing |
US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19916108C1 (en) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | 1,4-Benzothiazepine-1,1-dioxide derivatives substituted with sugar residues, process for their preparation and their use |
EP1382336B1 (en) * | 2001-04-25 | 2010-09-08 | Takeda Pharmaceutical Company Limited | Use of the abc expression promotor pioglitazone for the treatment of arteriosclerosis obliterans |
-
2002
- 2002-08-27 IL IL16043802A patent/IL160438A0/en unknown
- 2002-08-27 MX MXPA04001878A patent/MXPA04001878A/en unknown
- 2002-08-27 BR BR0212254-5A patent/BR0212254A/en not_active IP Right Cessation
- 2002-08-27 NZ NZ531346A patent/NZ531346A/en unknown
- 2002-08-27 KR KR10-2004-7002806A patent/KR20040032969A/en not_active Withdrawn
- 2002-08-27 PL PL02368843A patent/PL368843A1/en not_active Application Discontinuation
- 2002-08-27 WO PCT/JP2002/008629 patent/WO2003020315A1/en not_active Application Discontinuation
- 2002-08-27 EP EP02762874A patent/EP1421953A4/en not_active Withdrawn
- 2002-08-27 HU HU0401696A patent/HUP0401696A2/en unknown
- 2002-08-27 CN CNA028213645A patent/CN1589154A/en active Pending
- 2002-08-27 RU RU2004105965/15A patent/RU2004105965A/en not_active Application Discontinuation
- 2002-08-27 AU AU2002328569A patent/AU2002328569B9/en not_active Ceased
- 2002-08-27 CA CA002459017A patent/CA2459017A1/en not_active Abandoned
-
2004
- 2004-02-26 US US10/789,340 patent/US20040198788A1/en not_active Abandoned
- 2004-02-26 ZA ZA200401603A patent/ZA200401603B/en unknown
- 2004-03-16 CO CO04024652A patent/CO5560583A2/en unknown
- 2004-03-26 NO NO20041291A patent/NO20041291L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2002328569B2 (en) | 2005-09-22 |
HUP0401696A2 (en) | 2004-11-29 |
IL160438A0 (en) | 2004-07-25 |
KR20040032969A (en) | 2004-04-17 |
NO20041291L (en) | 2004-05-27 |
ZA200401603B (en) | 2004-10-19 |
BR0212254A (en) | 2004-10-19 |
NO20041291D0 (en) | 2004-03-26 |
WO2003020315A1 (en) | 2003-03-13 |
CN1589154A (en) | 2005-03-02 |
AU2002328569B9 (en) | 2005-10-27 |
PL368843A1 (en) | 2005-04-04 |
NZ531346A (en) | 2005-10-28 |
EP1421953A4 (en) | 2004-09-15 |
CA2459017A1 (en) | 2003-03-13 |
EP1421953A1 (en) | 2004-05-26 |
RU2004105965A (en) | 2005-05-10 |
CO5560583A2 (en) | 2005-09-30 |
US20040198788A1 (en) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU9393601A (en) | Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity | |
AU3652102A (en) | Compounds and their uses | |
DE60112974D1 (en) | Carbolinderivate | |
TW200505509A (en) | Tamper resistant transdermal dosage form | |
CY1108725T1 (en) | Combination of NMDA antagonist and acetylcholinesterase inhibitors for the treatment of ALZHEIMER | |
IL159022A0 (en) | Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | |
MXPA04000586A (en) | Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor. | |
EP2258381A3 (en) | Ghrelin analogs | |
DE60216233D1 (en) | Carbolinderivate | |
GB0002336D0 (en) | Medicaments | |
RS97604A (en) | New etonogestrel esters | |
ATE266420T1 (en) | COMBINATION PREPARATION CONTAINING SELECTIVE NMDA NR2B ANTAGONISTS AND COX-2 INHIBITORS | |
MY137620A (en) | Therapeutic treatment | |
ZA200305803B (en) | Prevention of diabetes by administration of GnRH antagonists. | |
IL145645A0 (en) | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | |
MXPA04001878A (en) | Medicinal compositions containing angiotensin ii receptor antagonist. | |
PL369736A1 (en) | New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors | |
IL166312A0 (en) | A pharmaceutical composition containing an adp receptor antagonist and an acat inhibitor | |
MXPA03008051A (en) | Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists. | |
AU2002258437A1 (en) | Peptide deformylase inhibitors | |
AU2002328569A1 (en) | Medicinal compositions containing angiotensin II receptor antagonist | |
PL359727A1 (en) | Crystalline pharmaceutical | |
GB0124844D0 (en) | Report generating system | |
MXPA04005226A (en) | 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof. | |
MY137953A (en) | New association of an anti-atherothrombotic agent and an anti-platelet-aggregation agent |